# Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

> **NCT00895895** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 526 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** SAM-531 1.5 mg
- **DRUG:** SAM-531 3.0 mg
- **DRUG:** SAM-531 5.0 mg
- **DRUG:** Donepezil

## Key facts

- **NCT ID:** NCT00895895
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 526 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2013-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895895, "Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00895895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*